+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic significance of platelet-to-lymphocyte ratio in non-small-cell lung cancer: a meta-analysis



Prognostic significance of platelet-to-lymphocyte ratio in non-small-cell lung cancer: a meta-analysis



Oncotargets and Therapy 9: 869-876



The platelet-to-lymphocyte ratio (PLR) is a useful predictive factor in several cancers. However, the prognostic value of PLR in patients with non-small-cell lung cancer (NSCLC) is still indistinct. Therefore, it was necessary for us to perform a meta-analysis to assess the prognostic value of PLR in patients with NSCLC. A systematic literature search was performed by using PubMed, EMBASE, and Web of Science databases for relevant studies until May 2015. Published studies investigating the association between PLR and overall survival (OS) and disease-free survival (DFS) were selected. Data from each eligible study were extracted. A meta-analysis was performed to analyze the prognostic value of PLR by using the hazard ratio (HR) and 95% confidence intervals (95% CI). A total of seven studies involving 1,554 patients were included in our meta-analysis. Our pooled results demonstrated that high PLR was associated with poor OS (HR: 1.60, 95% CI: 1.34-1.90, I (2)=22.3%, P heterogeneity = 0.259) and DFS (HR: 1.38, 95% CI: 1.11-1.73, I 2=0%, P heterogeneity = 0.482). Subgroup analysis between PLR and OS was performed in a further investigation. When the patients were segregated according to ethnicity, sample size, cutoff value, stage, and treatment modality, high PLR was also significantly correlated with OS. There was no significant heterogeneity among included studies. High PLR is associated with poor prognosis in patients with NSCLC. PLR may be a significant predictive biomarker in patients with NSCLC.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637268

Download citation: RISBibTeXText

PMID: 26955285

DOI: 10.2147/OTT.S96804


Related references

Meta-analysis of Platelet Lymphocyte Ratio as A Prognostic Factor for
Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi 22(5): 289-298, 2019

Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer. Clinical Lung Cancer 2019, 2019

Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer: a systemic review and meta-analysis. International Journal of Clinical and Experimental Medicine 8(3): 3098-3106, 2015

Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer. Cancer Management and Research 10: 5411-5422, 2018

Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients. International Journal of Cancer 139(1): 164-170, 2016

Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis. Annals of Surgical Oncology 23(2): 646-654, 2016

Total lymphocyte count, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio as prognostic factors in advanced non-small cell lung cancer with chemoradiotherapy. Cancer Management and Research 10: 6677-6683, 2018

Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. Thoracic Cancer 6(3): 275-287, 2015

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 111: 176-181, 2018

The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy. Indian Journal of Cancer 55(3): 276-281, 2019

Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor  in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Future Oncology 2018, 2018

Prognostic Significance of Combination of Preoperative Platelet Count and Neutrophil-Lymphocyte Ratio (COP-NLR) in Patients with Non-Small Cell Lung Cancer: Based on a Large Cohort Study. Plos One 10(5): E0126496, 2016

6PPrognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors. Annals of Oncology 30(Supplement_1), 2019

The Prognostic Factors of Lower Nadir of Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio Were Associated With Worse Treatment Outcomes in Patients With Limited-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology*biology*physics 99(2): E501-E502, 2017

Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: A meta-analysis. European Journal of Clinical Investigation 48(5): E12917, 2018